ArticleEndocrine2026
Optimising patient selection for adrenal vein sampling in primary aldosteronism: role of biochemical markers and scoring systems.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdrenal vein sampling (AVS) is the gold standard for subtyping primary aldosteronism (PA), but the role of adrenocorticotropic hormone (ACTH) stimulation during this procedure remains debated. AVS is technically challenging and is available at limited centres; strategies that limit its use to selected patient groups are needed.
methodsWe retrospectively analysed 98 patients with biochemically confirmed PA who underwent AVS between 2018 and 2025. Outcomes were compared between unstimulated (n = 31) and ACTH-stimulated (n = 67) protocols, including bilateral cannulation success, lateralization rates, and concordance with adrenal CT. Correlations between biochemical markers and the lateralization index (LI) were assessed, and composite clinical scores were validated and developed to predict unilateral disease.
resultsBilateral successful cannulation was achieved in 73.4% cases, with comparable rates between unstimulated and stimulated AVS (71.0% vs. 74.6%; p = 0.806). Lateralization was significantly higher in unstimulated AVS (68.2% vs. 34.0%; p = 0.027). CT-AVS concordance was low (44.9%). LI correlated positively with baseline plasma aldosterone (PAC), aldosterone-renin ratio (ARR), and post-saline PAC, and negatively with direct renin (DRC). Predictors of unilateral disease with sensitivity > 70% included PAC > 23.2 ng/dL, ARR > 17.7 ng/dL/mU/L and post-saline PAC > 8.38 ng/dL. The prediction score by Kobayashi et al. < 8 yielded sensitivity of 96.9% and specificity of 35% (AUC 0.712). Our composite score (PAC, ARR, male sex; threshold ≥ 20) achieved sensitivity of 81.5% and specificity of 65% (AUC 0.802).
conclusionsUnstimulated AVS provided superior lateralization without loss of cannulation success. Biochemical thresholds and clinical scoring may prioritise patients for AVS and simplify PA management algorithms.
Indexed as
Identifiers
42257763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.